ALNY ALNYLAM PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1178670 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY65.2%
TTM net income YoY239.7%
TTM EPS YoY206.9%
Revenue 3-yr CAGR53.0%
Net income 3-yr CAGR—
Margins
Gross margin81.8%
Operating margin13.5%
Net margin10.5%
FCF margin11.8%
EBITDA margin15.0%
Returns
ROE90.8%
ROA8.4%
ROIC (approx.)—
Asset turnover0.81x
Leverage & solvency
Liabilities / assets84.1%
Debt / equity0.00x
Current ratio2.76x
Interest coverage1.58x
Cash quality & payout
Operating cash flow / net income1.28x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026-03-312026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.46B | $1.29B | — | $1.10B | $1.25B | $773.69M | $594.19M | $593.17M |
| Cost of revenue | $361.75M | $298.26M | — | $267.72M | $197.23M | $142.03M | $70.18M | $102.65M |
| Gross profit | $1.10B | $992.69M | — | $829.31M | $1.05B | $631.66M | $524.01M | $490.52M |
| R&D expense | $408.54M | $413.13M | — | $372.22M | $358.81M | $323.62M | $265.12M | $300.17M |
| SG&A expense | $342.00M | $347.92M | — | $325.37M | $322.08M | $323.31M | $239.95M | $295.34M |
| Operating income | $345.80M | $231.44M | — | $131.72M | $367.98M | -$16.20M | $18.08M | -$105.16M |
| Interest expense | $84.37M | $82.05M | — | $129.34M | $67.46M | $61.46M | $58.31M | $38.97M |
| Pretax income | $295.81M | $177.81M | — | $86.26M | $280.57M | -$41.31M | -$2.37M | -$193.96M |
| Income tax | -$1.87B | $13.31M | — | -$25.28M | -$12.12M | $30.92M | $15.88M | -$110.19M |
| Net income | $2.17B | $164.49M | $205.99M | $186.42M | $292.68M | -$72.23M | -$18.25M | -$83.76M |
| EBITDA | $360.27M | — | — | $145.22M | $381.79M | -$2.25M | $32.48M | -$90.99M |
| EPS (basic) | 16.19 | 1.23 | — | — | 2.23 | -0.55 | -0.14 | — |
| EPS (diluted) | 15.72 | 1.21 | — | — | 2.14 | -0.55 | -0.14 | — |
| Weighted avg. shares (diluted) | 138.04M | 138.28M | — | — | 137.35M | 130.63M | 129.68M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.75B | $1.71B | — | $1.66B | $1.49B | $1.11B | $1.02B | $968.65M |
| Short-term investments | $1.83B | $1.60B | — | $1.25B | $1.23B | $1.74B | $1.61B | $1.72B |
| Receivables | $1.08B | $912.74M | — | $777.57M | $964.77M | $567.11M | $418.04M | $405.31M |
| Inventory | $105.91M | $97.11M | — | $82.72M | $75.38M | $71.69M | $65.58M | $78.51M |
| Current assets | $5.11B | $4.62B | — | $4.05B | $3.95B | $3.64B | $3.27B | $3.30B |
| PP&E, net | $614.91M | $554.14M | — | $513.15M | $501.75M | $499.79M | $498.68M | $502.78M |
| Total assets | $7.99B | $5.56B | — | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B |
| Current liabilities | $2.06B | $1.51B | — | $1.47B | $1.56B | $1.30B | $1.08B | $1.19B |
| Total liabilities | $4.39B | $4.20B | — | $4.18B | $4.62B | $4.32B | $4.10B | $4.17B |
| Shareholders' equity | $3.60B | $1.35B | $1.08B | $789.18M | $580.25M | $555.35M | $426.14M | $67.09M |
| Shares outstanding | 133.88M | 133.73M | — | 132.38M | 131.79M | 130.98M | 130.31M | 129.29M |
| Cash flow statement | ||||||||
| Operating cash flow | $340.99M | — | — | $163.56M | $296.86M | $153.73M | -$118.31M | -$94.66M |
| Capital expenditure | $69.83M | — | — | $23.29M | $12.14M | $14.29M | $8.97M | $9.09M |
| Free cash flow | $271.15M | — | — | $140.26M | $284.71M | $139.44M | -$127.28M | -$103.76M |
| Investing cash flow | -$311.74M | — | — | -$37.17M | $501.11M | -$141.38M | $113.77M | -$52.91M |
| Financing cash flow | $18.35M | — | — | $45.32M | -$420.09M | $53.76M | $44.08M | $31.00M |
| Depreciation & amortization | $14.48M | — | — | $13.51M | $13.80M | $13.94M | $14.40M | $14.17M |
| Stock-based compensation | $79.12M | $86.62M | — | $71.63M | $108.21M | $111.68M | $56.71M | $91.64M |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.